{"name":"Daewoong Pharmaceutical Co. LTD.","slug":"daewoong-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"daewoong.com","description":"","hq":"Seoul","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":47,"colorKey":"immunology","drugs":[{"name":"Novosis(bongros/BMP-2)","genericName":"Novosis(bongros/BMP-2)","slug":"novosis-bongros-bmp-2","indication":"Bone regeneration and fracture healing in orthopedic surgery","status":"phase_3"},{"name":"Axid Capsule 150mg","genericName":"Axid Capsule 150mg","slug":"axid-capsule-150mg","indication":"Other","status":"marketed"},{"name":"Clostridium Botulinum A Toxin","genericName":"Clostridium Botulinum A Toxin","slug":"clostridium-botulinum-a-toxin","indication":"Other","status":"marketed"},{"name":"Cresto","genericName":"Cresto","slug":"cresto","indication":"Other","status":"phase_1"},{"name":"Cresto 20mg","genericName":"Cresto 20mg","slug":"cresto-20mg","indication":"Other","status":"phase_1"},{"name":"DWC202404, DWC202314P","genericName":"DWC202404, DWC202314P","slug":"dwc202404-dwc202314p","indication":"Upper limb spasticity in adults","status":"phase_3"},{"name":"DWC202405, DWC202314","genericName":"DWC202405, DWC202314","slug":"dwc202405-dwc202314","indication":"Chronic sialorrhea","status":"phase_3"},{"name":"DWJ1276","genericName":"DWJ1276","slug":"dwj1276","indication":"Other","status":"phase_3"},{"name":"DWJ1464","genericName":"DWJ1464","slug":"dwj1464","indication":"Other","status":"marketed"},{"name":"DWJ1507","genericName":"DWJ1507","slug":"dwj1507","indication":"Other","status":"phase_3"},{"name":"Single group, open-label","genericName":"Single group, open-label","slug":"single-group-open-label","indication":"Other","status":"marketed"},{"name":"URSO Forte","genericName":"URSO Forte","slug":"urso-forte","indication":"Other","status":"marketed"},{"name":"Vemliver tablet","genericName":"Vemliver tablet","slug":"vemliver-tablet","indication":"Other","status":"marketed"},{"name":"(D) DWC202206","genericName":"(D) DWC202206","slug":"d-dwc202206","indication":"Other","status":"phase_3"},{"name":"Albis Tab","genericName":"Albis Tab","slug":"albis-tab","indication":"Other","status":"marketed"},{"name":"Baracross Tablet","genericName":"Baracross Tablet","slug":"baracross-tablet","indication":"Digestive support and gastrointestinal health","status":"marketed"},{"name":"DWC202011","genericName":"DWC202011","slug":"dwc202011","indication":"Other","status":"phase_3"},{"name":"DWC202202","genericName":"DWC202202","slug":"dwc202202","indication":"Other","status":"phase_1"},{"name":"DWC202304","genericName":"DWC202304","slug":"dwc202304","indication":"Phase 3 clinical trials are ongoing for DWC202304.","status":"phase_3"},{"name":"DWC202313, DWC202314","genericName":"DWC202313, DWC202314","slug":"dwc202313-dwc202314","indication":"Chronic sialorrhea","status":"phase_3"},{"name":"DWC202313, DWC202314P","genericName":"DWC202313, DWC202314P","slug":"dwc202313-dwc202314p","indication":"Chronic sialorrhea","status":"phase_3"},{"name":"DWC202404, DWC202314","genericName":"DWC202404, DWC202314","slug":"dwc202404-dwc202314","indication":"Chronic sialorrhea","status":"phase_3"},{"name":"DWC202405","genericName":"DWC202405","slug":"dwc202405","indication":"Irritable bowel syndrome (IBS) with diarrhea","status":"phase_3"},{"name":"DWC202405, DWC202314P","genericName":"DWC202405, DWC202314P","slug":"dwc202405-dwc202314p","indication":"Upper limb spasticity in adults","status":"phase_3"},{"name":"DWJ1177","genericName":"DWJ1177","slug":"dwj1177","indication":"Other","status":"phase_3"},{"name":"DWJ1252","genericName":"DWJ1252","slug":"dwj1252","indication":"Other","status":"phase_3"},{"name":"DWJ1319","genericName":"DWJ1319","slug":"dwj1319","indication":"Muscle wasting or sarcopenia (phase 3 development)","status":"phase_3"},{"name":"DWJ1506","genericName":"DWJ1506","slug":"dwj1506","indication":"Other","status":"phase_3"},{"name":"DWJ1567","genericName":"DWJ1567","slug":"dwj1567","indication":"Other","status":"phase_1"},{"name":"DWJ1609","genericName":"DWJ1609","slug":"dwj1609","indication":"Other","status":"phase_3"},{"name":"DWP14012 tablet A","genericName":"DWP14012 tablet A","slug":"dwp14012-tablet-a","indication":"Other","status":"phase_1"},{"name":"DWP16001 Amg","genericName":"DWP16001 Amg","slug":"dwp16001-amg","indication":"Other","status":"phase_3"},{"name":"DWP16001 drug A","genericName":"DWP16001 drug A","slug":"dwp16001-drug-a","indication":"Other","status":"phase_1"},{"name":"DWP212525 100mg","genericName":"DWP212525 100mg","slug":"dwp212525-100mg","indication":"Other","status":"phase_1"},{"name":"Envlo Tablet","genericName":"Envlo Tablet","slug":"envlo-tablet","indication":"Other","status":"phase_2"},{"name":"Envolomet SR Tablet","genericName":"Envolomet SR Tablet","slug":"envolomet-sr-tablet","indication":"Other","status":"phase_2"},{"name":"Erdos, Talion","genericName":"Erdos, Talion","slug":"erdos-talion","indication":"Other","status":"phase_1"},{"name":"Fexuprazan Hydrochloride","genericName":"Fexuprazan Hydrochloride","slug":"fexuprazan-hydrochloride","indication":"Gastroesophageal reflux disease (GERD)","status":"marketed"},{"name":"Gasmotin","genericName":"Gasmotin","slug":"gasmotin","indication":"Other","status":"phase_3"},{"name":"Megavec","genericName":"Megavec","slug":"megavec","indication":"Other","status":"phase_1"},{"name":"Mucotra SR Tablet 150mg","genericName":"Mucotra SR Tablet 150mg","slug":"mucotra-sr-tablet-150mg","indication":"Other","status":"marketed"},{"name":"Placebo of DWJ1252","genericName":"Placebo of DWJ1252","slug":"placebo-of-dwj1252","indication":"Other","status":"phase_3"},{"name":"Placebo of DWJ1464","genericName":"Placebo of DWJ1464","slug":"placebo-of-dwj1464","indication":"Other","status":"marketed"},{"name":"Placebo of Gasmotin","genericName":"Placebo of Gasmotin","slug":"placebo-of-gasmotin","indication":"Control arm in clinical trials for Gasmotin (active ingredient: mosapride or similar prokinetic agent)","status":"phase_3"},{"name":"Talion","genericName":"Talion","slug":"talion","indication":"Other","status":"phase_1"},{"name":"Tiropramide HCl 100mg","genericName":"Tiropramide HCl 100mg","slug":"tiropramide-hcl-100mg","indication":"Other","status":"marketed"},{"name":"Ursodeoxycholic acid, thiamine, riboflavin","genericName":"Ursodeoxycholic acid, thiamine, riboflavin","slug":"ursodeoxycholic-acid-thiamine-riboflavin","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"DWP450","genericName":"DWP450","slug":"dwp450","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DWP14012 A mg","genericName":"DWP14012 A mg","slug":"dwp14012-a-mg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DWP14012 B mg","genericName":"DWP14012 B mg","slug":"dwp14012-b-mg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DWP712 inj.","genericName":"DWP712 inj.","slug":"dwp712-inj","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DWJ211","genericName":"DWJ211","slug":"dwj211","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DWP14012","genericName":"DWP14012","slug":"dwp14012","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DWP14012 X mg","genericName":"DWP14012 X mg","slug":"dwp14012-x-mg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DWP14012 Y mg","genericName":"DWP14012 Y mg","slug":"dwp14012-y-mg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DWP16001","genericName":"DWP16001","slug":"dwp16001","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"DWP708","genericName":"DWP708","slug":"dwp708","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Metformin 1500mg, QD","genericName":"Metformin 1500mg, QD","slug":"metformin-1500mg-qd","indication":"Type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"(P) DWC202207","genericName":"(P) DWC202207","slug":"p-dwc202207","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"(D) DWC202207","genericName":"(D) DWC202207","slug":"d-dwc202207","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"(P) DWC202206","genericName":"(P) DWC202206","slug":"p-dwc202206","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Atorvastatin 40mg, QD","genericName":"Atorvastatin 40mg, QD","slug":"atorvastatin-40mg-qd","indication":"Hypercholesterolemia and dyslipidemia","status":"phase_3"},{"name":"Olmetec","genericName":"Olmetec","slug":"olmetec","indication":"Hypertensive disorder","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Clostridium Botulinum Toxin Type A","genericName":"Clostridium Botulinum Toxin Type A","slug":"clostridium-botulinum-toxin-type-a","indication":"Cervical dystonia","status":"marketed"},{"name":"DWN12088","genericName":"DWN12088","slug":"dwn12088","indication":"Relapsing forms of multiple sclerosis","status":"phase_2"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Envlomet SR Tablet","genericName":"Envlomet SR Tablet","slug":"envlomet-sr-tablet","indication":"Chronic pain","status":"phase_2"}]}],"pipeline":[{"name":"DWP450","genericName":"DWP450","slug":"dwp450","phase":"phase_3","mechanism":"DWP450 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Novosis(bongros/BMP-2)","genericName":"Novosis(bongros/BMP-2)","slug":"novosis-bongros-bmp-2","phase":"phase_3","mechanism":"Novosis is a recombinant human bone morphogenetic protein-2 (BMP-2) that promotes bone formation by stimulating osteoblast differentiation and new bone growth.","indications":["Bone regeneration and fracture healing in orthopedic surgery","Spinal fusion procedures"],"catalyst":""},{"name":"(P) DWC202207","genericName":"(P) DWC202207","slug":"p-dwc202207","phase":"phase_3","mechanism":"DWC202207 is a drug that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Axid Capsule 150mg","genericName":"Axid Capsule 150mg","slug":"axid-capsule-150mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Clostridium Botulinum A Toxin","genericName":"Clostridium Botulinum A Toxin","slug":"clostridium-botulinum-a-toxin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cresto","genericName":"Cresto","slug":"cresto","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cresto 20mg","genericName":"Cresto 20mg","slug":"cresto-20mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DWC202404, DWC202314P","genericName":"DWC202404, DWC202314P","slug":"dwc202404-dwc202314p","phase":"phase_3","mechanism":"DWC202404 is a botulinum toxin type A inhibitor.","indications":["Upper limb spasticity in adults","Cervical dystonia in adults","Blepharospasm in adults"],"catalyst":""},{"name":"DWC202405, DWC202314","genericName":"DWC202405, DWC202314","slug":"dwc202405-dwc202314","phase":"phase_3","mechanism":"DWC202405 and DWC202314 are both botulinum toxin type A serotypes.","indications":["Chronic sialorrhea","Upper limb spasticity"],"catalyst":""},{"name":"DWJ1276","genericName":"DWJ1276","slug":"dwj1276","phase":"phase_3","mechanism":"DWJ1276 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"DWJ1464","genericName":"DWJ1464","slug":"dwj1464","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DWJ1507","genericName":"DWJ1507","slug":"dwj1507","phase":"phase_3","mechanism":"DWJ1507 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"DWP14012 A mg","genericName":"DWP14012 A mg","slug":"dwp14012-a-mg","phase":"phase_3","mechanism":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"DWP14012 B mg","genericName":"DWP14012 B mg","slug":"dwp14012-b-mg","phase":"phase_3","mechanism":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"DWP712 inj.","genericName":"DWP712 inj.","slug":"dwp712-inj","phase":"phase_3","mechanism":"DWP712 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Single group, open-label","genericName":"Single group, open-label","slug":"single-group-open-label","phase":"marketed","mechanism":"Unable to determine specific mechanism without drug name or identifier.","indications":[],"catalyst":""},{"name":"URSO Forte","genericName":"URSO Forte","slug":"urso-forte","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vemliver tablet","genericName":"Vemliver tablet","slug":"vemliver-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"(D) DWC202206","genericName":"(D) DWC202206","slug":"d-dwc202206","phase":"phase_3","mechanism":"DWC202206 is an investigational therapeutic in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"(D) DWC202207","genericName":"(D) DWC202207","slug":"d-dwc202207","phase":"phase_3","mechanism":"DWC202207 is a drug that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"(P) DWC202206","genericName":"(P) DWC202206","slug":"p-dwc202206","phase":"phase_3","mechanism":"DWC202206 is a drug that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Albis Tab","genericName":"Albis Tab","slug":"albis-tab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atorvastatin 40mg, QD","genericName":"Atorvastatin 40mg, QD","slug":"atorvastatin-40mg-qd","phase":"phase_3","mechanism":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","indications":["Hypercholesterolemia and dyslipidemia","Primary and secondary prevention of cardiovascular disease","Reduction of risk of myocardial infarction and stroke"],"catalyst":""},{"name":"Baracross Tablet","genericName":"Baracross Tablet","slug":"baracross-tablet","phase":"marketed","mechanism":"Baracross is a herbal combination tablet that works through multiple plant-derived compounds to support metabolic and digestive function.","indications":["Digestive support and gastrointestinal health"],"catalyst":""},{"name":"Clostridium Botulinum Toxin Type A","genericName":"Clostridium Botulinum Toxin Type A","slug":"clostridium-botulinum-toxin-type-a","phase":"marketed","mechanism":"Clostridium botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Hemifacial spasm","Chronic migraine","Spasticity"],"catalyst":""},{"name":"DWC202011","genericName":"DWC202011","slug":"dwc202011","phase":"phase_3","mechanism":"DWC202011 is an investigational therapeutic in Phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"DWC202202","genericName":"DWC202202","slug":"dwc202202","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DWC202304","genericName":"DWC202304","slug":"dwc202304","phase":"phase_3","mechanism":"DWC202304 is a therapeutic agent that targets a specific molecular pathway.","indications":["Phase 3 clinical trials are ongoing for DWC202304."],"catalyst":""},{"name":"DWC202313, DWC202314","genericName":"DWC202313, DWC202314","slug":"dwc202313-dwc202314","phase":"phase_3","mechanism":"DWC202313 and DWC202314 are botulinum toxin type A inhibitors.","indications":["Chronic sialorrhea","Upper limb spasticity"],"catalyst":""},{"name":"DWC202313, DWC202314P","genericName":"DWC202313, DWC202314P","slug":"dwc202313-dwc202314p","phase":"phase_3","mechanism":"DWC202313 and DWC202314P are botulinum toxin type A inhibitors.","indications":["Chronic sialorrhea","Upper limb spasticity"],"catalyst":""},{"name":"DWC202404, DWC202314","genericName":"DWC202404, DWC202314","slug":"dwc202404-dwc202314","phase":"phase_3","mechanism":"DWC202404 and DWC202314 are botulinum toxin type A serotypes used for the treatment of various conditions.","indications":["Chronic sialorrhea","Upper limb spasticity"],"catalyst":""},{"name":"DWC202405","genericName":"DWC202405","slug":"dwc202405","phase":"phase_3","mechanism":"DWC202405 is a small molecule drug that targets the mechanism of action of a specific enzyme.","indications":["Irritable bowel syndrome (IBS) with diarrhea"],"catalyst":""},{"name":"DWC202405, DWC202314P","genericName":"DWC202405, DWC202314P","slug":"dwc202405-dwc202314p","phase":"phase_3","mechanism":"DWC202405 is a botulinum toxin type A inhibitor.","indications":["Upper limb spasticity in adults","Cervical dystonia in adults"],"catalyst":""},{"name":"DWJ1177","genericName":"DWJ1177","slug":"dwj1177","phase":"phase_3","mechanism":"DWJ1177 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"DWJ1252","genericName":"DWJ1252","slug":"dwj1252","phase":"phase_3","mechanism":"DWJ1252 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"DWJ1319","genericName":"DWJ1319","slug":"dwj1319","phase":"phase_3","mechanism":"DWJ1319 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.","indications":["Muscle wasting or sarcopenia (phase 3 development)"],"catalyst":""},{"name":"DWJ1506","genericName":"DWJ1506","slug":"dwj1506","phase":"phase_3","mechanism":"DWJ1506 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"DWJ1567","genericName":"DWJ1567","slug":"dwj1567","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DWJ1609","genericName":"DWJ1609","slug":"dwj1609","phase":"phase_3","mechanism":"DWJ1609 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"DWJ211","genericName":"DWJ211","slug":"dwj211","phase":"phase_3","mechanism":"DWJ211 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"DWN12088","genericName":"DWN12088","slug":"dwn12088","phase":"phase_2","mechanism":"DWN12088 is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"DWP14012","genericName":"DWP14012","slug":"dwp14012","phase":"phase_3","mechanism":"DWP14012 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"DWP14012 X mg","genericName":"DWP14012 X mg","slug":"dwp14012-x-mg","phase":"phase_3","mechanism":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"DWP14012 Y mg","genericName":"DWP14012 Y mg","slug":"dwp14012-y-mg","phase":"phase_3","mechanism":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"DWP14012 tablet A","genericName":"DWP14012 tablet A","slug":"dwp14012-tablet-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DWP16001","genericName":"DWP16001","slug":"dwp16001","phase":"phase_3","mechanism":"DWP16001 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"DWP16001 Amg","genericName":"DWP16001 Amg","slug":"dwp16001-amg","phase":"phase_3","mechanism":"DWP16001 is an AMG (likely referring to a specific molecular scaffold or mechanism class) in development by Daewoong Pharmaceutical, currently in Phase 3 trials.","indications":[],"catalyst":""},{"name":"DWP16001 drug A","genericName":"DWP16001 drug A","slug":"dwp16001-drug-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DWP212525 100mg","genericName":"DWP212525 100mg","slug":"dwp212525-100mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DWP708","genericName":"DWP708","slug":"dwp708","phase":"phase_2","mechanism":"DWP708 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Envlo Tablet","genericName":"Envlo Tablet","slug":"envlo-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Envlomet SR Tablet","genericName":"Envlomet SR Tablet","slug":"envlomet-sr-tablet","phase":"phase_2","mechanism":"Envlomet SR Tablet is a sustained-release formulation of a selective alpha-2 adrenergic receptor agonist.","indications":["Chronic pain"],"catalyst":""},{"name":"Envolomet SR Tablet","genericName":"Envolomet SR Tablet","slug":"envolomet-sr-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Erdos, Talion","genericName":"Erdos, Talion","slug":"erdos-talion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fexuprazan Hydrochloride","genericName":"Fexuprazan Hydrochloride","slug":"fexuprazan-hydrochloride","phase":"marketed","mechanism":"Fexuprazan hydrochloride is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease"],"catalyst":""},{"name":"Gasmotin","genericName":"Gasmotin","slug":"gasmotin","phase":"phase_3","mechanism":"Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9","indications":[],"catalyst":""},{"name":"Megavec","genericName":"Megavec","slug":"megavec","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Metformin 1500mg, QD","genericName":"Metformin 1500mg, QD","slug":"metformin-1500mg-qd","phase":"phase_3","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Mucotra SR Tablet 150mg","genericName":"Mucotra SR Tablet 150mg","slug":"mucotra-sr-tablet-150mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Olmetec","genericName":"Olmetec","slug":"olmetec","phase":"phase_1","mechanism":"Type-1 angiotensin II receptor, Type-1 angiotensin II receptor","indications":["Hypertensive disorder"],"catalyst":""},{"name":"Placebo of DWJ1252","genericName":"Placebo of DWJ1252","slug":"placebo-of-dwj1252","phase":"phase_3","mechanism":"This is a placebo control and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of DWJ1464","genericName":"Placebo of DWJ1464","slug":"placebo-of-dwj1464","phase":"marketed","mechanism":"A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo of Gasmotin","genericName":"Placebo of Gasmotin","slug":"placebo-of-gasmotin","phase":"phase_3","mechanism":"This is a placebo formulation with no active pharmacological mechanism.","indications":["Control arm in clinical trials for Gasmotin (active ingredient: mosapride or similar prokinetic agent)"],"catalyst":""},{"name":"Talion","genericName":"Talion","slug":"talion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tiropramide HCl 100mg","genericName":"Tiropramide HCl 100mg","slug":"tiropramide-hcl-100mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ursodeoxycholic acid, thiamine, riboflavin","genericName":"Ursodeoxycholic acid, thiamine, riboflavin","slug":"ursodeoxycholic-acid-thiamine-riboflavin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPVlo0UlJ3YmZfN1Foa3J1end3NHMyb0hXekVqQ0h3X2l6SVFwcnZlQkdGNXhqZzFGZWMwTUxxZkU5QTBZcUNGNDRheUIxWWVkMkZySm9qMXU0bnVadmVaMGRHdEF6RjU3SDJWM0VqNWQyaUJlUkNWY3puLUNIb1pSbk1HZEtBZFNkdmlkN1EzTmM4bjFkNkFpRHc0NjlZRnpWMDE1VGhkUzg?oc=5","date":"2025-06-17","type":"deal","source":"BioWorld News","summary":"Korea biotech roundup: four financings, six R&D deals mid-June - BioWorld News","headline":"Korea biotech roundup: four financings, six R&D deals mid-June","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNaWNRWmhwVHFMaEt0amVGLWttZGZfektCQVpVaTVQcjZXMG1SZW5KT25ZYmM0ZnpYVlBlQWZUNVhsZkZpSF9BMGdBdDFwTDRxT0dGeEJWb2l1VjdmVnhSS3gtd1pCSUY2elBKeTMtOVJFU1NZbFkwdzhlWVNvbnFOTVJyNFpYcEVwY25DNWotUS1oVXpWYUp2ZTdtRW9UdERmekFmYk1XZ3pkNWVKZnc3X0JiQWRDM0FHeGRLZERjYnFWam1zaTNCOFhDYzhHbHduMF8yT2R2OEtxejEyZ05iWU5lREdJLVVjcEs2WFdkNk1MaFU?oc=5","date":"2025-06-11","type":"deal","source":"BioSpace","summary":"Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics - BioSpace","headline":"Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOTEpaTDNHSnlGcE9reGQtZ0Z5bkZWTFpGQU9OcjlzRkx6cFpxOXk3U2xJSG41QUVuTjhwZWlxZ0lEXzZGSFNHRFRtejM4ZmVRQTQxZkNBRDBXMjN6NmxyQkRzMGlidXFpWTVNWFVFRjVuc2Vjd2ZBN1E1Wjllc0NGdS1kdmFJNUI3Y0d5YlpSNHpvUUZENmNFMlhGQWhXUkVzRTRN?oc=5","date":"2025-04-01","type":"deal","source":"BioWorld News","summary":"Daewoong sees end of CS Pharma deal; new starts in cancer, DTx - BioWorld News","headline":"Daewoong sees end of CS Pharma deal; new starts in cancer, DTx","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBNeWJySlNUUGdhTm11dkVQNXRJOWJVa0F3a3owMzdZYk12UU4yQzFIOUU0YXVYSnJBTmM4OWxIdjhZSEd4VTQ3OUV5LUo0MmEtVjlrSjB5a21vV181c3Uyd2ozeEE3NFNKQm1NWkh30gFyQVVfeXFMTVBZRC1HNXp3QU44b1Flc1Q2Y1RKalJuYm43ZU1Uc2xsMDJQaHF6dGFOM1kyTkRQbmpUTjh0aGJLZm5lU285VTJPLUx4MFdadm45b05QVGEtNEJlMXRabTN2SkhMU3V2aTlnOTdsdDNneEJn?oc=5","date":"2024-12-12","type":"pipeline","source":"koreabiomed.com","summary":"Daewoong Pharmaceutical leads consortium to develop once-monthly obesity drug - koreabiomed.com","headline":"Daewoong Pharmaceutical leads consortium to develop once-monthly obesity drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxONWhOLU5qOUhpSV9kaFYtVW94VS1LNlluNXlxaFF0NXJES0xVVndtMWZLUzVpaldHSlJ6d3ppb1ZNOVlwYzZrWjdsVldYWEJYeXdieENCQk12Z1ppRF9tSDZRc0hzUFFjWC1oNTN5aWFXdS1lZktUUHJhVUpMWHY3YnM2UWxwT2U1eW5xMXBuWXBoSUxZVS1XMGxXcDBVZTVsbU1fdkczN2E0cDljOHBETXpfMDRUZkViVC1FbGM0dy1PbHhRc25FcWJUVzRCTzFtYnNQZm5EOXBUMDg2TGtBUlNidXdtUFNrLUZpcUF2S1dXV1Y2S2UtRFAyUVpCemdyb2V3RUxsZFNGMUJ2R1poMGhxd01Mek42d01kLTVEWkJIT0NrempzdXlYXzc2S1NYRTBmd0paZE9OZkdpY2Fzay1GOWVkTUJuaTdzQm5JVngtWDZRMG1qU01KMjk5T0ty?oc=5","date":"2024-11-25","type":"trial","source":"PR Newswire","summary":"HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease - PR Newsw","headline":"HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQQVZsNnZTOVpTZEEyRWhoenZIelpPdjVfTmdSeG5kTWg2dUNudVVvT0pWU2dia2Z2TUJQTElPQkc4TElBUGllMDBQbVUwNEUxVVBUWUlyaFE0ZmhRUjE2Tk9FZEdib0swVEpTTk52akNUbkNEaHNIcTBUNlV1LUhfMGlnSWpmMnZV?oc=5","date":"2024-02-06","type":"pipeline","source":"BioSpace","summary":"Daewoong Pharmaceutical Announces 2023 Financial Results - BioSpace","headline":"Daewoong Pharmaceutical Announces 2023 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxPZ1BSeHVNVThwMFljUVlZVXJhT2ctcXhONkxqa0tkc3AwSjExNU1CaW1Ud1VVbGxScFdxTF84SHNuUDJkSmIwYktwX0pfR0J1RnpmZTU2Z3paeVl0ZV9kNlV5X19VYnR1MU1kS3BYMXg2MVA4bEhuT3hSLXVWLTdJbkxtandJWTVkaExPQUQ0RmZpM0p6ajdCYUM0Q05BUHI0NVM1cUd2bW1ldzA1SGtlcVIyenUzcFVsclQxc3V5RlVBV2VDS2hnZ2k5SWc3R1VjVkRUS0hyRzRiNFlYeFFJLUdLd0UxMHlYc3J6azNCTEhtUU1vd3JwdEZSTWdyS2ZwbjBkdTVtbkxycXQwZXRYWHBPc3BFOE5HZlA3OFJhOS1BUl9PUW91eW5YMEtFNFE?oc=5","date":"2023-05-25","type":"pipeline","source":"PR Newswire","summary":"HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease - PR Newswire","headline":"HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxQSFB5N2dQbW5FUHdTQVN1bTlYOTBRQXd3c0tkcEM5VG42NV9FS3lKeWliTnR6VDhuSXYxeUNtTjZiSHVwakNRRkNQUkg5SWxRRG1IblhkOXFWOHYxd2FReEpmVlZCY1hZczI2MDZKWGtNU1dkUzk4ZEM5RXZBSnZWcnVsNDZKZGI3VTlEZ1BJSGJUd3B2RDZObU1lc24zS293VFc4NkRYOXZ0Z09Wd0NBMDhfeHJMYXIyRl9ndnFiUmdMZzJaRENLQ0J6NUxUX1N3ODRfdVd2Z29WdXUtZGwxcHdJMnF3WXhyUG1lV0tEeHE3eGtDVW1fM1MyT0JPRmRrY0NuMTJYSDJ0S3VWUWRUal82U0Z5N2lGZWdR?oc=5","date":"2023-04-27","type":"deal","source":"PR Newswire","summary":"Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio - PR Newswire","headline":"Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9xSWNkY29LMmpqRTJPRXI1eUZMMGVwVUlsRmYwejZSRUxZem1mYWVIRVhLcV9sVUN3MVZHMktqQWU5dVAyYldjTDhNMWpSNXM5SU4yWkNCZEtrQ0d6NjA0anFJRmt3LXExdFVHRVJn?oc=5","date":"2023-02-24","type":"pipeline","source":"KED Global","summary":"Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico - KED Global","headline":"Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1nMTMzanJtNlNpUExRMW85azlZN2lveGY0Mm5wdzhHVk1OeVcydDJvTGhqMnZsXzNSYkFvZFFBRzk5d1BiS1FUdHZvMkpNSDFtRjFfLTZVTndBbUNUazhreURCU2F3dDE0MDRnMGJR?oc=5","date":"2023-02-10","type":"pipeline","source":"KED Global","summary":"Korean court rules Daewoong poached Medytox’s botox strain - KED Global","headline":"Korean court rules Daewoong poached Medytox’s botox strain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBud1ZJdzhiZldLSHZ6clVWaS1vYVdqWk5ZSjJ3NUhvcGoyY1FldVFDRjNEdUFrUTdXWmUxaUIxYzZkMHBudll4eDNackc4QTFlR1Zfd0hwUFZOSEo3V3pwWVo0QzJubWVMODg3Z0t30gFyQVVfeXFMTW9XTXBVR3EySHNuNXdmV1VZMnV4Z0Q0R0JwVTBRMkwwRm1qNms5OUtRdHhxcUs3cHF1Q1BBUGMzWmhJZThYMGdRWmtKOEVjQzR4aTIzWnNGekkyWWVEZzk5MG8wN3VNcDNmY196ZC1LbFF3?oc=5","date":"2022-09-29","type":"pipeline","source":"koreabiomed.com","summary":"Daewoong, AZothBio to co-research AI-based new cancer drugs - koreabiomed.com","headline":"Daewoong, AZothBio to co-research AI-based new cancer drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOMlVTeEdUamE3OVFCNHE4bzV5WUFMWV9qTEt0U1BhWHVBQk9hOG42NXNpenRoMUthdFJ4N3dDR2MzRTZkVzZMbjhWeWhxVlF5eHlOWTJOM041RXpqUlprOV9zdHdQU041bDN2bGFOek1pLWJKaUJOcGF2UUVnaVJCMTNscFg4NEd2dWJEZ0NVdUJjUzVmOFhyYTA5RldHY3ByNEFuNGo5eUt6akxmM3p2RWs0TEl0amRQUm1xeHp6M0k4Sm9PVzM1QzAtUFNJN0Rq?oc=5","date":"2020-10-12","type":"regulatory","source":"Reuters","summary":"S.Korea's Daewoong Pharma gets approval for Phase 1 trials of COVID-19 anti-parasite drug - Reuters","headline":"S.Korea's Daewoong Pharma gets approval for Phase 1 trials of COVID-19 anti-parasite drug","sentiment":"positive"}],"patents":[],"drugCount":66,"phaseCounts":{"phase_3":36,"marketed":14,"phase_1":11,"phase_2":5},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}